Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
64.69
UNCHANGED
Streaming Delayed Price
Updated: 4:15 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
37,557
Open
64.69
Bid (Size)
64.59 (9)
Ask (Size)
64.65 (11)
Prev. Close
64.69
Today's Range
64.69 - 64.69
52wk Range
60.47 - 87.67
Shares Outstanding
N/A
Dividend Yield
1.44%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
Today 7:00 EST
From
AstraZeneca
Via
Business Wire
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
November 07, 2024
From
AstraZeneca
Via
Business Wire
Performance
YTD
-5.42%
-5.42%
1 Month
-15.84%
-15.84%
3 Month
-20.97%
-20.97%
6 Month
-16.65%
-16.65%
1 Year
+1.83%
+1.83%
More News
Read More
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Via
Benzinga
Why Is AstraZeneca Stock Sinking On Tuesday?
November 05, 2024
Via
Benzinga
Smart Money Is Betting Big In AZN Options
November 04, 2024
Via
Benzinga
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
November 04, 2024
Via
Talk Markets
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
November 04, 2024
Via
Benzinga
3 Magnificent Stocks Under $100 to Buy in November
November 03, 2024
Via
The Motley Fool
3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
October 31, 2024
Via
The Motley Fool
Monopar Therapeutics Skyrockets 400% on Licensing Deal
October 25, 2024
Via
MarketBeat
Exposures
COVID-19
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
October 25, 2024
Via
Benzinga
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
October 24, 2024
Via
Benzinga
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
Via
Investor's Business Daily
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
October 11, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
Via
Benzinga
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
October 08, 2024
Via
The Motley Fool
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
October 07, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Open Lower; Dow Tumbles Over 150 Points
October 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
October 07, 2024
Via
Benzinga
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
October 07, 2024
From
AstraZeneca
Via
Business Wire
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Via
Benzinga
Exposures
Product Safety
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Via
Investor's Business Daily
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
October 03, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.